[{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Icosabutate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ venBio Partners"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosabutate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosabutate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Icosabutate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : NST-4016 (icosabutate), is a once-daily, oral SEFA currently in Phase 2b clinical trial for non-alcoholic steatohepatitis. It has demonstrated dose-dependent and significant improvements in all liver function parameters as well as in inflammatory and fib...

                          Brand Name : NST-4016

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 05, 2023

                          Lead Product(s) : Icosabutate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile.

                          Brand Name : NST-4016

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 08, 2021

                          Lead Product(s) : Icosabutate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Proceeds will be used to progress the SEFA development pipeline: Completion of Ph 2b study of lead programme Icosabutate in (NASH) Initiation of clinical development of two new programmes for (PNALD)

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 08, 2020

                          Lead Product(s) : Icosabutate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : venBio Partners

                          Deal Size : $40.0 million

                          Deal Type : Series B Financing

                          blank